Welcome to our dedicated page for BridgeBio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma stock.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a pioneering commercial-stage biopharmaceutical company that specializes in the discovery, creation, and delivery of transformative medicines for patients suffering from genetic diseases and cancers with clear genetic drivers. Established in 2015, the company is headquartered in Palo Alto, California. BridgeBio's mission is to address significant unmet medical needs through genetic medicine by leveraging a comprehensive pipeline of development programs that span from early-stage scientific research to late-stage clinical trials.
The company's core focus areas include Mendelian diseases, Genetic Dermatology, Oncology, and Gene Therapy. BridgeBio’s innovative approach involves systematically mapping the genetic disease landscape to identify promising therapeutic assets. Their proprietary platform and management expertise are harnessed to accelerate the development of these early-stage assets into clinically impactful treatments.
BridgeBio’s robust pipeline boasts several notable programs:
- Acoramidis (AG10): Aiming to treat transthyretin amyloid cardiomyopathy (ATTR-CM), this next-generation, orally-administered TTR stabilizer has shown positive results in the Phase 3 ATTRibute-CM trial. The New Drug Application (NDA) for acoramidis has been accepted by the FDA, with a target decision date set for November 29, 2024.
- Infigratinib: Targeting achondroplasia and hypochondroplasia, this FGFR1-3 inhibitor aims to address skeletal dysplasias. The PROPEL 2 Phase 2 trial has demonstrated significant and sustained increases in growth velocity.
- BBP-418: Designed for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), this glycosylation substrate is under Phase 3 trials, with the potential for accelerated approval based on recent interactions with the FDA.
BridgeBio's track record includes successful capital raises, strategic partnerships, and a series of public offerings that have strengthened its financial positioning. The company recently completed a $200 million private financing for its oncology subsidiary, BridgeBio Oncology Therapeutics, to accelerate the development of its precision oncology pipeline.
Key recent developments include:
- The initiation of a comprehensive equity grants program to attract top talent in the biopharmaceutical industry.
- Positive results from multiple clinical trials, including significant improvements in health-related quality of life measures for patients with ATTR-CM treated with acoramidis.
- Ongoing collaborations with global pharmaceutical leaders like Bayer for the commercial development and distribution of key assets in international markets.
BridgeBio remains committed to advancing genetic medicine and delivering groundbreaking therapies to improve patient lives. For more information, visit bridgebio.com and follow them on LinkedIn and Twitter.
BridgeBio Pharma (Nasdaq: BBIO) reported its Q4 and full-year 2022 financial results, ending the year with $466.2 million in cash and equivalents, down from $787.7 million in 2021. The company incurred a net loss of $484.7 million for the year, with revenues decreasing to $77.6 million from $69.7 million. Key clinical trials continue, including the Phase 3 ATTRibute-CM trial for acoramidis, with topline data expected mid-2023, and the PROPEL 2 trial for infigratinib, expected to report in March 2023. Operating expenses decreased due to restructuring efforts, with total operating costs at $589.9 million.
On February 13, 2023, BridgeBio Pharma (Nasdaq: BBIO) granted 11 new employees restricted stock units totaling 59,800 shares of common stock. These awards were made under the company’s 2019 Inducement Equity Plan, adhering to Nasdaq Listing Rule 5635(c)(4). BridgeBio, a biopharmaceutical firm founded in 2015, focuses on creating medicines for genetic diseases and cancers, leveraging advances in genetic medicine. The company’s pipeline ranges from early-stage research to advanced clinical trials.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced a roundtable discussion on February 16, 2023, focusing on the medical and social implications of achondroplasia. The discussion will feature Dr. Melita Irving, a clinical geneticist at Guy's and St Thomas' NHS Foundation Trust, who is known for her expertise in genetic and rare conditions, particularly skeletal dysplasia. The event aims to shed light on the challenges faced by individuals with achondroplasia and explore new treatment options. The live webcast will be accessible on the BridgeBio website, with a replay available for 90 days.
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company, announced participation in several investor conferences in February and March 2023. Key events include the SVB Securities Global Biopharma Conference on February 14 at 2:20 PM ET, the Goldman Sachs Bus Tour on March 1 at 8:00 AM PT, and the Cowen 43rd Annual Healthcare Conference on March 8 at 10:30 AM ET.
Live webcasts will be available on the company's website, with replays accessible for 90 days post-event. Founded in 2015, BridgeBio focuses on developing transformative medicines for genetic diseases and cancers.
BridgeBio Pharma (Nasdaq: BBIO) will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 9, 2023, at 3:00 pm PT. The event will feature members of its management team discussing the company's advancements in genetic diseases and cancer treatments. Investors can access a live webcast through the BridgeBio website and a replay will be available for 90 days post-event. Founded in 2015, BridgeBio focuses on developing transformative medicines for patients with genetic conditions and cancer with clear genetic drivers.
BridgeBio Pharma has initiated the pivotal CALIBRATE Phase 3 trial of encaleret for treating autosomal dominant hypocalcemia type 1 (ADH1). This study aims to assess the efficacy of encaleret compared to standard care over 24 weeks, focusing on achieving normal blood and urinary calcium levels. Preliminary Phase 2 results showed that 69% of participants met these targets without standard care. If successful, encaleret could be the first approved therapy specifically for ADH1, impacting an estimated 25,000 patients in the US and EU.
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases and cancers, will present at two upcoming investor conferences. The first, the Jefferies Health Care Conference, will be held in London, UK on November 15 at 9:40 am ET. The second, the Evercore ISI HealthCONx Conference, will take place virtually on November 30 at 10:05 am ET. Live webcasts of the presentations can be accessed via the company's website, with replays available for 90 days following each event.
BridgeBio Pharma reported promising developments in its drug pipeline, including positive preclinical data for BBO-8520, a KRASG12C inhibitor, and updated 12-month Phase 2 results for BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i. Recent trials showed no serious adverse events for infigratinib in achondroplasia. Q3 2022 operating expenses were $129.5 million, down 26.2% from Q1 2022, with cash reserves totaling $558.3 million, ensuring operational stability into 2024. The company continues to progress key trials while actively managing costs.
BridgeBio Pharma (Nasdaq: BBIO) will host an investor call on October 17, 2022, at 1:30 pm ET, to discuss two advanced RAS precision oncology programs, including BBO-8520, a KRAS G12C GTP/GDP dual inhibitor, and a novel PI3Kα:RAS breaker mechanism. BBO-8520 has shown significant potency in KRAS models compared to first-generation inhibitors, with strong activity in vivo and the potential to overcome resistance mechanisms. The PI3Kα:RAS program aims for broad applicability in RAS-driven tumors and potentially avoids hyperglycemia, a common side effect of existing PI3Kα inhibitors.
BridgeBio Pharma announced promising results from a Phase 2 study of its investigational therapy BBP-418 for limb-girdle muscular dystrophy type 2i (LGMD2i). After 12 months, patients showed significant improvements, including a more than 75% reduction in creatine kinase levels and enhancements in functional measures like the north star assessment for dysferlinopathy. The novel assay developed to evaluate alpha-dystroglycan (αDG) glycosylation indicated potential disease modification. Plans to initiate a Phase 3 trial in 2023 are underway, aiming to fill a significant treatment gap for LGMD2i patients.
FAQ
What is the current stock price of BridgeBio Pharma (BBIO)?
What is the market cap of BridgeBio Pharma (BBIO)?
What does BridgeBio Pharma, Inc. specialize in?
What are the core focus areas of BridgeBio Pharma's pipeline?
What are some key programs in BridgeBio's pipeline?
What recent financial achievements has BridgeBio Pharma accomplished?
Has BridgeBio Pharma formed any significant partnerships?
What recent clinical trial results has BridgeBio Pharma announced?
When was BridgeBio Pharma founded?
Where is BridgeBio Pharma headquartered?
What is the therapeutic approach of BridgeBio Pharma?